- Home
- IXHL vs ANTX Comparison
IXHL vs ANTX Comparison
Compare IXHL & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IXHL
- ANTX
- Stock Information
- Founded
- IXHL 2001
- ANTX 2017
- Country
- IXHL Australia
- ANTX United States
- Employees
- IXHL N/A
- ANTX N/A
- Industry
- IXHL
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- IXHL
- ANTX Health Care
- Exchange
- IXHL Nasdaq
- ANTX Nasdaq
- Market Cap
- IXHL 39.2M
- ANTX 31.9M
- IPO Year
- IXHL N/A
- ANTX 2022
- Fundamental
- Price
- IXHL $2.00
- ANTX $1.00
- Analyst Decision
- IXHL
- ANTX Buy
- Analyst Count
- IXHL 0
- ANTX 4
- Target Price
- IXHL N/A
- ANTX $2.50
- AVG Volume (30 Days)
- IXHL 43.4K
- ANTX 407.6K
- Earning Date
- IXHL 09-30-2024
- ANTX 11-13-2024
- Dividend Yield
- IXHL N/A
- ANTX N/A
- EPS Growth
- IXHL N/A
- ANTX N/A
- EPS
- IXHL N/A
- ANTX N/A
- Revenue
- IXHL $86,000.00
- ANTX N/A
- Revenue This Year
- IXHL N/A
- ANTX N/A
- Revenue Next Year
- IXHL N/A
- ANTX N/A
- P/E Ratio
- IXHL N/A
- ANTX N/A
- Revenue Growth
- IXHL N/A
- ANTX N/A
- 52 Week Low
- IXHL $0.80
- ANTX $0.87
- 52 Week High
- IXHL $12.68
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- IXHL 41.84
- ANTX 30.50
- Support Level
- IXHL $2.22
- ANTX $0.99
- Resistance Level
- IXHL $3.12
- ANTX $1.14
- Average True Range (ATR)
- IXHL 0.28
- ANTX 0.03
- MACD
- IXHL -0.04
- ANTX -0.01
- Stochastic Oscillator
- IXHL 0.00
- ANTX 6.67
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.